Skip to content

Helping patients reclaim a life of possibility

Menu
  • About us
  • Contact us
logo MPE
  • Myeloma and AL Amyloidosis
    • About myeloma
    • About AL amyloidosis
  • What we do
      • Member and patient community programmes
        • Myeloma Awareness Month
        • MPE Masterclass
        • Scholarship programme
        • Care Connect Programme
        • Myeloma CABs
        • MPE Myeloma and AL amyloidosis Community Taskforce
        • Advocate Development Programme
        • European Young Myeloma Patients Group
        • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • Research
        • Patient Evidence
        • Horizon Europe
        • IMI
      • Access and Policy
        • Myeloma Access Atlas
        • CEE workgroup on Access
        • Myeloma and AL amyloidosis Clinical Trial Navigator
        • EU HTA regulation
    • Member and patient community programmes
      • MPE Masterclass
      • Scholarship programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • European Young Myeloma Patients Group
    • Research
      • Patient Evidence
      • Horizon Europe
      • IMI
    • Access and Policy
      • Myeloma Access Atlas
      • CEE workgroup on Access
      • Myeloma and AL amyloidosis Clinical Trial Navigator
      • EU HTA regulation
  • Educational Resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Patient guides
  • European Myeloma Day
  • News
logo MPE
  • Myeloma and AL Amyloidosis
    • About myeloma
    • About AL amyloidosis
  • What we do
      • Member and patient community programmes
        • Myeloma Awareness Month
        • MPE Masterclass
        • Scholarship programme
        • Care Connect Programme
        • Myeloma CABs
        • MPE Myeloma and AL amyloidosis Community Taskforce
        • Advocate Development Programme
        • European Young Myeloma Patients Group
        • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • Research
        • Patient Evidence
        • Horizon Europe
        • IMI
      • Access and Policy
        • Myeloma Access Atlas
        • CEE workgroup on Access
        • Myeloma and AL amyloidosis Clinical Trial Navigator
        • EU HTA regulation
    • Member and patient community programmes
      • MPE Masterclass
      • Scholarship programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • European Young Myeloma Patients Group
    • Research
      • Patient Evidence
      • Horizon Europe
      • IMI
    • Access and Policy
      • Myeloma Access Atlas
      • CEE workgroup on Access
      • Myeloma and AL amyloidosis Clinical Trial Navigator
      • EU HTA regulation
  • Educational Resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Patient guides
  • European Myeloma Day
  • News
logo MPE
Dominik Candea

DOMINIK CANDEA

Dominik joined MPE as a Medical and Scientific Officer in March 2025.

Dominik holds a Master of Science degree in Biology from the Johannes Gutenberg University Mainz, Germany. During his studies, Dominik gained early experience in the fields of cancer biology, immunology and hematology. He conducted research on Glioblastoma, Acute Myeloid Leukemia and Graves’ disease and worked as a tutor teaching biology and medical students and was also working part-time for MPE. In 2023, Dominik started a Marie Curie Research Fellowship at the University of Turin, Italy, where he worked on Anaplastic Large Cell Lymphoma, a rare type of Non-Hodgkin Lymphoma. His passion for science and education led him to rejoin MPE as a Medical and Science Officer in spring 2025. Dominik is fluent in Romanian, German, English and Italian. He is currently based in Germany.

 

Recent Posts

EMA committee recommends teclistamab plus daratumumab for relapsed or refractory multiple myeloma

3 July 2026

On 25 June 2026, the Committee for Medicinal Products for Human Use (CHMP) recommended extending the approved use of teclistamab (Tecvayli®) to include its use in combination with daratumumab for…

Read more

MPE joins patient organisations call for stronger patient voice in EU health technology assessments

1 July 2026

Myeloma Patients Europe has joined 14 other patient organisations members of the European Union Health Technology Assessment (EUHTA) stakeholder network to issue a joint statement on the publication of the…

Read more

MPE Advocate helps launch Luxembourg’s first myeloma information day

30 June 2026
Read more

Supporting those who care: Introducing the MPE Care Connect Programme

25 June 2026

Myeloma Patients Europe (MPE) is proud to announce the launch of the Care Connect Programme, a new initiative dedicated to strengthening support for carers of people living with myeloma and AL amyloidosis…

Read more

EHA 2026 interviews and highlights

17 June 2026

MPE at EHA 2026: Stockholm in review EHA 2026 brought thousands of researchers, clinicians and patient advocates together in Stockholm for four days of cutting-edge science, discussion and connection. For…

Read more

European Commission approves subcutaneous isatuximab for the treatment of multiple myeloma

9 June 2026

On 8 June 2026, the European Commission approved the subcutaneous (under the skin) formulation of isatuximab (Sarclisa®) for use in all myeloma indications currently approved for the intravenous (IV) formulation…

Read more
mpe logo negativo 300x249 1

Myeloma Patients Europe AISBL

Avenue Louise 143/4, 1050
Brussels Belgium
© Myeloma Patients Europe 2026
  • Contact
  • About us
  • Privacy policy
  • Terms and conditions
  • Cookies Policy
Go to Top
logo MPE
  • About MPE
    • Our members
    • Our board and staff
    • Medical Advisory Committee
    • Our Strategic Goals
    • Our funding
    • Get involved in MPE activities
    • Become a member
  • Contact us
  • Myeloma and AL Amyloidosis
    • About myeloma
    • About AL amyloidosis
  • What we do
    • Member and patient community programmes
      • Myeloma Awareness Month
      • MPE Masterclass
      • Scholarship programme
      • Care Connect Programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • European Young Myeloma Patients Group
    • Research
      • Patient Evidence
      • Horizon Europe
      • IMI
    • Access and Policy
      • Myeloma Access Atlas
      • CEE workgroup on Access
      • Myeloma and AL amyloidosis Clinical Trial Navigator
      • EU HTA regulation
  • Educational Resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Patient guides
  • News
  • European Myeloma Day

PopUp

  • This field is for validation purposes and should be left unchanged.